Treatments & Services

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.





  • Nivolumab for Esophageal Squamous Cell Carcinoma

    A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation





  • Trilaciclib/Placebo with Atezolizumab in Small Cell Lung Cancer

    Phase 2 Study of Carbplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive Stage Small Cell Lung Cancer

  • Nivolumab in Advanced NSCLC

    A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies


  • ABP798 versus Rituximab in Non-Hodgkin Lymphoma

    A Randomized, Double-blind study evaluating the efficacy, safety and immunogenicity of ABP 798 compared with Rituximab in subjects with CD20 postiive B-Cell Non-Hodgkin Lymphoma (NHL)

  • Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

    A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above

  • Rituximab +/- Ibrutinib for Follicular Lymphoma

    A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

  • TGR-1202 in patients with DLBCL, FL, SLL, or MZL

    A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

  • Lenalidomide/Rituxan for FL, MZ, ML

    A phase 3b randomized study of Lenalidomide (CC-5013) plus Rituximab maintenance therapy followed by Lenalidomide single-agent maintenance versus Rituximab maintenance in subjects with relapsed/refractory Follicular, Marginal Zone or Mantle Cell Lymphoma




Solid Tumors